Quanterix
| General Information | |
| Business: | We are a life sciences company that has developed a next generation, ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics. Our platform enables customers to reliably detect protein biomarkers in extremely low concentrations in blood, serum and other fluids that, in many cases, are undetectable using conventional, analog immunoassay technologies. |
| Industry: | LABORATORY ANALYTICAL INSTRUMENTS |
| Employees: | 122 |
| Founded: | 2007 |
| Contact Information | |
| Address | 113 Hartwell Avenue, Lexington, MA 02421, US |
| Phone Number | (617) 301-9400 |
| Web Address | http://www.quanterix.com |
| View Prospectus: | Quanterix |
| Financial Information | |
| Market Cap | $317.85mil |
| Revenues | $23.0 mil (last 12 months) |
| Net Income | $-31.4 mil (last 12 months) |
| IPO Profile | |
| Symbol | QTRX |
| Exchange | NASDAQ |
| Shares (millions): | 4.3 |
| Price range | $15.00 - $15.00 |
| Est. $ Volume | $64.1 mil |
| Manager / Joint Managers | J.P. Morgan/ Leerink Partners |
| CO-Managers | BTIG/ Evercore ISI |
| Expected To Trade: | 12/7/2017 |
| Status: | Priced |
| Quiet Period Expiration Date: | Available only to Subscribers |
| Lock-Up Period Expiration Date: | Available only to Subscribers |
| SCOOP Rating | Available only to Subscribers |
| Rating Change | Available only to Subscribers |